Olshan Represents Pharmacyclics in Successful $207.2 Million Public Offering

Firm News

Olshan represented Pharmacyclics Inc., a NASDAQ-listed clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, in a $207.2 million overnight public offering of 2.2 million shares of its common stock.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.